Michael Arad

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

Iacopo Olivotto, Artur Oręziak, Roberto Barriales‐Villa et al. · The Lancet · 2020 · 1.1K citations · Full text

Cardiomyopathy, Structural Heart Disease, Cardiovascular Disease +2

Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases

Pablo García‐Pavía, Claudio Rapezzi, Yehuda Adler et al. · European Heart Journal · 2021 · 1.1K citations · Full text

Glycogen Storage Diseases Presenting as Hypertrophic Cardiomyopathy

Michael Arad, Barry J. Maron, Joshua Gorham et al. · New England Journal of Medicine · 2005 · 641 citations

Metabolic Syndrome, Cardiomyopathy, Heart Failure +15

Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Philippe Charron, Michael Arad, Eloisa Arbustini et al. · European Heart Journal · 2010 · 483 citations · Full text

Cardiomyopathy, Genetic Testing, Heart Failure +14

Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy

Michael Arad, D. Woodrow Benson, Antonio R. Pérez‐Atayde et al. · Journal of Clinical Investigation · 2002 · 461 citations · Full text